Background: Objectives were to provide an overview and understand the strength of evidence and extent of potential biases and validity of claimed associations between body mass index (BMI) and risk of developing cancer.
Introduction
Cancer is the leading cause of death both in developed and developing countries [1] and the overall burden of cancer is increasing due to an aging global population as well as continued exposure to known risk factors such as smoking, obesity, and dietary patterns [2] . Among these, high body mass index (BMI) has emerged as a major threat in increasing the incidence and mortality of cancers. Worldwide, it has been reported that 481 000 or 3.6% of all new cancer cases in adults (aged 30 years and older after the 10-year lag period) in 2012 were attributable to high BMI [3] .
Because individual studies have reported conflicting results, there have been several dose response meta-analyses studying associations between BMI and cancer risk (see the supplementary references, available at Annals of Oncology online). However, some of these reported associations could be caused by biases from each study favoring the publication of significant associations [2] .
In order to provide an overview of the strength of evidence, the extent of potential biases and the validity of the claimed associations between BMI and risk of developing various kinds of cancer, we here carried out an umbrella review of the evidence across published dose response meta-analyses.
Methods

Literature search strategy
We carried out an umbrella review and re-analyzed the meta-analyses on the dose-response association of observational epidemiological studies between BMI and various types of cancer risk. Two investigators (JIS and EKC) independently searched PubMed and Embase limited to articles written in the English language. The search terms were: '(BMI OR obesity) AND (cancer OR carcinoma OR neoplasm) AND (meta-analysis OR systematic review) AND (dose response)'. We identified relevant articles by examining titles, abstracts, full texts in order and discussed and resolved any discrepancies by reaching consensus between two investigators (JIS and EKC). The detailed process of screening and selecting articles is presented in supplementary Figure S1 , available at Annals of Oncology online.
Eligibility and inclusion/exclusion criteria
We included only dose-response meta-analyses of epidemiological studies assessing relations between BMI and the risk for various types of cancer. We excluded meta-analyses that studied the association between obesity or weight itself (overweight, weight gain, waist to hip ratio, etc.) and cancer risk to evaluate the dose-response relationship between BMI and cancer risk. We also excluded meta-analyses that examined prognosis relating increased BMI and the risk of cancer-related mortality (dying from cancer). If there was more than one meta-analysis on the same topic, we included all meta-analyses to compare the summary estimates in the duplicate meta-analyses.
Extraction of the data
The data were independently extracted by two investigators (JIS and EKC) and any discrepancy was discussed and resolved by consensus. For each eligible dose-response meta-analysis, we abstracted and recorded information on the name of authors, journal name, publication year/ month, the type of cancer, the epidemiological study design (casecontrol or cohort), the number of included studies, the number of cases and the random summary effects with 95% confidence intervals (CI), the patterns of dose-response relationship (linear or nonlinear) between BMI and cancer risk. Among the included meta-analyses, we also investigated meta-analyses with detailed raw data by performing re-analyses.
Estimation of summary effects and estimation of prediction interval
For the main findings of each eligible dose-response meta-analysis, we re-analyzed the data by performing meta-analysis and estimated the summary effects and 95% CI using both inverse variance random-and fixedeffects models [4] . We also calculated and presented the 95% prediction intervals (PIs), which address the dispersion of effects (in 95% of cases the true effect in a new study will fall within the PIs) and further account for between-study heterogeneity [5] , whereas CI reflect the accuracy of the mean.
Evaluation of between-study heterogeneity and small study effects
We evaluated the between-study heterogeneity using the I 2 metric of inconsistency and the p value of the v 2 -based Cochran Q test [6] . I 2 values of <25%, 25%-50%, and >75% are usually judged to represent low, moderate (large), and high (very large) heterogeneity, respectively [7] .
We used the regression asymmetry test proposed by Egger et al. for the evaluation of small study effects [8] . A P value <0.05 in random-effects meta-analyses was judged to constitute evidence for small-study effects.
Addition of big data or unselected (missed) individual studies to the results of updated published meta-analyses
We also carried out meta-analyses after adding recently published big data or unselected (missed) individual studies to the results of updated published meta-analyses to evaluate whether these analyses could change the main results of updated meta-analyses. All analyses were done using Comprehensive meta-analysis Software version 2.0 (Borenstein, NH).
Level of evidence of the associations
We further divided the associations between BMI and cancer risk according to the following criteria: whether there is a strong statistical significance by fixed-effects and random-effects meta-analyses at P < 0.001 (a threshold that has been suggested to substantially reduce the number of false positive findings) [4] , the number of cases is more than 1000, 95% PI excluded null, between-study heterogeneity was not large (I 2 < 50%), and there is no evidence of small-study effects.
Convincing evidence. There was a strong statistical significance in fixed-effects and random-effects meta-analyses at P < 0.001, 95% PI excluded null, there was no large between-study heterogeneity and no small study effects.
Suggestive evidence. Significance threshold for the random summary effects (P < 0.05), but 95% PI included the null and there was not large between-study heterogeneity and there were no small study effects.
Weak (probable) evidence. Significance threshold for the random summary effects (P < 0.05), but 95% PI included the null, there was large between-study heterogeneity or small study effects.
Nonsignificant associations. No significance threshold for the random summary effects (P > 0.05).
However, if the heterogeneity is large, we rechecked the results whether it may be due to differences in the direction of the effect or it can be due to differences in the size of the association although all studies may show increased risk. In the latter case, we re-determined the level of evidence again.
Results
Overall summary of results
We re-analyzed the data of meta-analyses on associations of increased BMI and the risk of 20 specific cancers. First, in the reanalyses of the meta-analyses by Renehan et al. [9] , only five associations (with endometrial cancer, male esophageal adenocarcinoma, male and female renal cancer, and male multiple myeloma) were convincing (Table 1) . ) and P-value of the Cochran Q test for evaluation of heterogeneity.
PI, prediction interval. ) and P-value of the Cochran Q test for evaluation of heterogeneity.
Second, we re-analyzed data from updated meta-analyses on the associations between increased BMI and the risk of various cancers that were reported after the publication of Renehan et al. [9] (Table 2) . We found that there have been few updated meta-analyses and that these were predominantly restricted to certain cancers. There were few changes since the results of meta-analyses by Renehan et al. [9] . However, while there was no association between increased BMI and the risk of liver and ovarian cancer in the study by Renehan et al. [9] , positive associations were found in updated meta-analyses which are in accordance with an increase in the number of individual studies. However, PI included the null in these two cancers. In addition, there were two new meta-analyses on the associations between increased BMI and the risk of bladder cancer and brain [central nervous system (CNS)] tumors [10, 11] . There was a positive association between increased BMI and the risk of bladder cancers in only fixed effect meta-analyses and there was a positive association between increased BMI and the risk of brain (CNS) tumors with large heterogeneity. The evidence for pancreatic cancer changed from weak to convincing in accordance with increasing the number of individual studies (Table 2) .
Third, we carried out meta-analyses after inclusion of the recently published big dataset from the UK [12] to the results of updated published meta-analyses to evaluate whether these analyses would change the main results of the previous metaanalyses. There were no significant differences in the main results between updated meta-analyses and the meta-analyses in which the big dataset of Bhaskaran et al. [12] was added in most cancers (Table 3) .
Fourth, if there were unselected (missed) individual studies between updated published meta-analyses and Renehan et al.'s data [9] , we also carried out new meta-analyses to obtain the final conclusion. We also added the recently published big data from the UK [12] to the results of updated published metaanalyses or Renehan et al.'s data [9] (if there was no updated meta-analyses in some cancers) to evaluate whether these analyses can change the main results of the previous meta-analyses. We found that although the results from most updated metaanalyses as well as our re-meta-analyses were not different from those of Renehan et al. [9] , the level of evidence was changed in some cancers such as leukemia in which the evidence for the positive association was weak in the report of Renehan et al. [9] , but became convincing after adding data from Bhaskaran et al. [12] (Table 4) .
There were significant associations of increased BMI and the risk of 14 cancers (random effects) and 17 cancers (fixed effects) with the application of 95% CI rules, but the application of 95% PI excluded the null in only 8 cancers (colon, rectal, endometrial, leukemia, lung cancer, multiple myeloma, pancreatic, and renal cell carcinoma). Large heterogeneity was found in 12 cancers and small study effects were found in 3 cancers. The direction of meta-analyses results was discordant to that of the largest study in four cancers (brain and CNS, multiple myeloma, nonHodgkin's lymphoma and prostate cancers). Detailed results of the evidence regarding the association of 20 cancers with BMI are summarized in Tables 1-4 and described in the supplementary material, available at Annals of Oncology online. Table 4 . Reanalysis of the meta-analyses by combining all the data on associations of increased BMI and the risk of 20 specific cancers (Table 5 ). There were consistent results among them for several cancers, but inconsistent ones in some cancers. Also, the RRs of IARC were higher than ours in various cancers. These different results may be due to the different principles and statistical methods to determine the level of evidence and the dissimilar inclusion criteria of individual studies. For examples, we determined the level of evidence according to the PI, the degree of heterogeneity and publication bias and we only included the dose-response meta-analyses of epidemiological studies assessing relations between BMI and the risk for various types of cancer and excluded meta-analyses that studied the association between obesity or weight itself (overweight, weight gain, waist to hip ratio, etc.) and cancers.
Discussion
Our study determined the level of evidence for the associations between increased BMI and the risk of 20 specific cancers by putting various criteria through re-analyses of the meta-analyses in addition to an umbrella review. Attention should be paid to interpret the results of meta-analyses taking into account not only the effect size and 95% CI but also information regarding, e.g. the heterogeneity, publication bias or the position within a funnel plot [15] . Clinicians generally see the RR with 95% CI in determining the associations between the two variables. However, these associations are questionable if the studies show a high heterogeneity or publication bias [6, 16] . In addition, some authors recently suggested that robust meta-analytic conclusions mandate the provision of PI in meta-analysis summaries in addition to 95% CI [17] and there have been several reports on the usefulness of PI in determining the level of evidence by umbrella review [6, 16] . The meta-analysis carried out by Renehan et al. [9] published in the year 2008 is currently still the most extensive and well conducted study reporting on the associations between increased BMI and the risk of various cancers. They showed the effect size with 95% CI and heterogeneity among studies and carried out meta-analyses according to gender, but did not show the publication bias. Regarding heterogeneity, the results should be interpreted with caution, as it can also be due to other various factors such as, e.g. ethnicity, smoking status, or magnitudes in the size of the association (like endometrial cancer in our analyses). This does not mean the results are unreliable.
In our study, we found that the direction of meta-analyses results were discordant to that of the largest study [12] in four cancers (Brain and CNS, multiple myeloma, non-Hodgkin's lymphoma and prostate cancers) in which the direction of meta-analyses results were concordant to that of the largest study in updated or Renehan et al.'s meta-analyses [9] . Cappelleri et al. reported that results of smaller studies are usually compatible with the results of large studies, but discrepancies do occur even when the diversity among both large studies and smaller studies is taken into consideration [18] . Recently, the integration of 'big data' science into the practice of epidemiology was emphasized as one of the eight overarching thematic recommendations proposed by the National Cancer Institute to provide a vision for cancer epidemiology to the scientific community in the 21st century [19] . However, Hoffman and Podgurski questioned whether 'big data' are necessarily better data because (i) the data contained in biomedical databases is surprisingly likely to be incorrect or incomplete; (ii) systematic biases, arising from both the nature of the data and the preconceptions of investigators, are serious threats to the validity of research results, especially in answering causal questions; and (iii) datamining of biomedical databases makes it easier for individuals with political, social, or economic agendas to generate ostensibly scientific but misleading research findings for the purpose of manipulating public opinion and swaying policymakers [20] . Overlapping meta-analyses on the same topic or errors in performing meta-analyses can be problematic in the field of metaanalyses [21] . To overcome these problems, we carried out an umbrella review which has some important advantages because it systematically collects and evaluates information from multiple systematic reviews and meta-analyses on all clinical outcomes for which these meta-analyses were carried out [22] and re-metaanalyzed the previous meta-analyses comprehensively to obtain the final conclusions by combining the individual studies of multiple meta-analyses which may overcome the problems suggested above.
However, our study still has several limitations. First, we included only dose-response meta-analyses and excluded meta-analyses related to obesity or weight gain. Second, we only carried out the reanalyses with data from reports from which re-meta-analyses were possible and therefore we might have missed relevant individual studies. Third, we could not perform re-meta-analyses according to gender, smoking status, or ethnicity, which should therefore be interpreted based on the summary of the umbrella review summarized in the supplementary Table S1 , available at Annals of Oncology online. When stratified by smoking status in lung cancer, linear dose-response associations were observed for current smokers, ex-smokers and nonsmokers (P nonlinearity > 0.05), whereas the effects were attenuated when restricting analysis to nonsmokers [23] . Fourthly, the application of PI, heterogeneity and publication bias may not be definitive criteria.
In conclusion, we comprehensively re-analyzed the data of dose-response meta-analyses on the associations between BMI and cancers by adding big data or combinations of missed individual studies which lead to changes in the original conclusions in some types of cancers, which was not covered in the recently published other umbrella review [24] . In the future, metaanalyses on this topic should include individual patient data meta-analyses by sharing data, sub-group analyses according to the various factors, and by removing biases or errors from big data or original meta-analyses.
